Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04258683 |
| Title | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Canadian Myeloma Research Group |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| CancerCare Manitoba | Winnipeg | Manitoba | R3E0V9 | Canada | Details | |
| The Moncton Hospital | Moncton | New Brunswick | E1C6Z8 | Canada | Details | |
| CIUSSS de l'Estrie-CHUS | Sherbrooke | Quebec | J1H5N4 | Canada | Details | |
| Allan Blair Cancer Centre | Regina | Saskatchewan | S4T7T1 | Canada | Details |